• Foreign Affairs
  • Money Matters
  • Domestic Affairs
  • IT, Innovation and Startups
 

Talk Finance

£$$€№₮IAL €¢¤₦¤MI¢ №€₩$
  • Foreign Affairs
  • Money Matters
  • Domestic Affairs
  • IT, Innovation and Startups

Talk Finance

  • Foreign Affairs
  • Money Matters
  • Domestic Affairs
  • IT, Innovation and Startups

In Foreign Affairs

AstraZeneca vaccine becomes flashpoint in EU/UK tensions

29th January 2021

AstraZeneca vaccine becomes flashpoint in EU/UK tensions Pin It

The contract concluded by the European Union with the COVID-19 vaccination manufacturer AstraZeneca has been made public. The agreement, which will, at the request of the company, so far, a secret, it was a lot to do, since AstraZeneca has announced tentative, much less vaccine than had been agreed upon.

In the contract published by the European Commission on Friday, the number of doses of AstraZeneca delivered, when and from which plant was eliminated. EU sources say that the British-Swedish company promised 80 million doses in the first three months of the year, or actually 120 million. AstraZeneca announced last week that it could not produce more than 31 million doses due to delays in a Belgian vaccine factory.

That is not enough for the EU. AstraZeneca should, if necessary, supply the EU with vaccines from its British factories, even if, according to the company, they are intended for the United Kingdom. The contract provides that AstraZeneca will endeavour “to the best of its ability” to produce the agreed amount of vaccines in factories in Belgium, Italy/Ireland and the United Kingdom. Which factories are precisely intended is not visible.

The agreement that AstraZeneca should do its best is also an important point of contention. The top man of AstraZeneca used that as a defence rather: his company promised no result, but only an effort. But that provoked the anger of the EU, which maintains that it was only about the development and not the delivery of the vaccine.

Nor is the EU paying for the vaccine visible in the agreement. The AstraZeneca vaccine is expected to be approved for use in the union later in the day.

39 million doses offered

The vaccine maker would have offered to deliver 39 million doses earlier this week. But that is still far too little, according to an EU source. At the latest consultation so far between AstraZeneca and the European Commission and the EU countries, on Wednesday evening, the manufacturer would not have increased that bid.

Many EU countries, including the Netherlands, have heavily used AstraZeneca’s vaccine. The Netherlands had hoped to receive millions of vaccines in February and March, but with what is now on the table it would have to do with about 1.2 to 1.5 million.

Sunday means president of the commission, Ursula von der Leyen, a meeting with the directors of each of the six producers in the EU, the contracts have ended.

Share

No Comments

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Previous Post

EasyJet passenger flow down…

In Money Matters

EasyJet passenger flow down by 87 percent

View Post

Next Post

Britain expects no disruptions in…

In Foreign Affairs

Britain expects no disruptions in vaccine supplies

View Post

In Foreign Affairs

5,000 Hong Kong residents signed for British papers

View Post

In Money Matters

British retail is hit harder than was expected

View Post

In Money Matters

EasyJet wants to make COVID-19 test for the crew mandatory

View Post

Boris Johnson

In Domestic Affairs

Boris Johnson comes with the long roadmap from the lockdown

View Post

Newsletter

Latest News

View

EU zone economic confidence reaches 93.4 with the reasons for euphoria still to uncover

25th February 2021

View

Moody’s expects lower bounceback for Eurozone and Britain

24th February 2021

Boris Johnson

View

Boris Johnson comes with the long roadmap from the lockdown

23rd February 2021

View

EasyJet wants to make COVID-19 test for the crew mandatory

22nd February 2021

Allow us to introduce ourselves

Talk-Finance.co.uk, the analytic media. We are focused on the fresh business, M&A and financial data. We pay attention to the interesting new projects and startups while not letting the whole picture to let unnoticed.

  • Investing.com
  • Runch.co.uk

Sign Up for Our Newsletter

Our friendly crew

  • Matthew Patridge, the chief Editor
  • Chris Kimble, the managing Editor
  • Matthew Weller, webmaster&technical stuff
  • Charles Sizemore, author
  • David Stevenson, author
  • Helen Rush, author

Contact us by [email protected]

© 2019 Talk Finance - All Rights Reserved. [email protected]